A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease

NCT ID: NCT00413647

Last Updated: 2013-06-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30
• Study Completion Date: 2008-02-29

Brief Summary

Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85. Nine normal controls will undergo repeated whole body imaging for biodistribution and dosimetry estimation. Six other normal healthy subjects will undergo heart imaging only. Six CAD subjects will undergo heart imaging only.

Detailed Description

CardioPET™ is a modified fatty acid (MFA) that closely resembles naturally-occurring free fatty acids (FFAs) in the human body.

Study Procedures:

Visit 1: Screening - Eligibility determination

Visit 2: Injection and PET Imaging

Visit 3: Follow-up Visit

Conditions

Coronary Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

CardioPET

Group Type: EXPERIMENTAL

CardioPET

Intervention Type: DRUG

Interventions

CardioPET

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Normal Healthy Volunteers:

• Subject must provide written informed consent prior to any study related procedures
• Subjects must be between the ages of 50 and 85 years of age.

Coronary Artery Disease (CAD) subjects:

• Subjects must provide written informed consent prior to any study related procedures;
• Subjects must be ≥ 50 and ≤ 85 years of age;
• Subject must have history of CAD documented by an exercise stress Myocardial Perfusion Imaging (MPI) study within 6 months documenting myocardial infarct without ischemia.

Exclusion Criteria

Normal Healthy Volunteers:

• Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination
• Any clinically significant abnormality in the screening laboratory tests or ECG
• Fasting blood glucose level over 120 mg/dl
• Any exposure to any investigational drugs with four(4)weeks prior to Visit 1
• Any exposure to radiopharmaceuticals within four(4)weeks prior to the date of Visit 1
• Any new prescription medications within four(4)weeks of Visit 1
• Subject has a Positive(+)Serum and/or Urine Pregnancy Test or is lactating, or the possibility of pregnancy cannot be ruled out prior to dosing. There are standard pregnancy procedures for use of radiopharmaceuticals in research at MGH

Coronary Artery Disease (CAD) Subjects:

• Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the possibility of pregnancy cannot be ruled out prior to dosing;
• Any clinically significant acute or unstable physical or psychological disease judged by the investigators based on medical history or screening physical examination;
• Coronary artery bypass graft (CABG) within 1 year;
• Percutaneous coronary intervention (PCI), with stent placement within three months;
• Blood pressure over 180/100;
• Acute changes in ECG;
• Cardiac ischemia identified by MPI stress test;
• Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction, cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical procedures;
• Any implanted pacemaker or defibrillator use within the last three months;
• Inability to remain in camera for approximately 60 minutes (Smokers and COPD are included as long as they can breath in PET camera and not taking O2 through nasal canola);
• History of Diabetes Mellitus;
• Serum creatinine > 2 mg/dL;
• All cancer and or chemotherapy patients;
• Body Mass Index (BMI) is over 35;
• Any exposure to any investigational drugs or medical device within four (4) weeks prior to imaging study;
• Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of imaging study;
• High daily alcohol consumption over 4 alcohol drinks per day.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Fluoropharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alan J. Fischman, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

CardioPET P-01

Identifier Type: -

Identifier Source: org_study_id